Which leukemia has a median survival rate of approximately 10 years?

Chronic Lymphocytic Leukemia (CLL) is characterized by a prolonged clinical course and generally has a more indolent progression compared to acute leukemias. The median survival rate of approximately 10 years reflects how patients diagnosed with CLL often live for extended periods, especially with advances in treatment options, including targeted therapies and monoclonal antibodies. While the prognosis can vary based on factors such as genetic abnormalities and response to therapy, the overall survival rates have improved over time, contributing to the approximately 10-year median survival.

In contrast, the other types of leukemia mentioned typically have different prognoses. Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) are acute forms of leukemia and usually have poorer survival rates, particularly if not treated promptly and effectively. Chronic Myeloid Leukemia (CML), on the other hand, has also shown improved survival due to advancements in tyrosine kinase inhibitors, but its median survival can be lower than that of CLL in the earlier phases of the disease without treatment. Therefore, CLL stands out with a more favorable long-term prognosis, highlighted by its median survival rate.